Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis

doi:10.1111/his.70033

Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis

2026-01-01

1

PRE

AI

Chien‐Kuang Cornelia Ding *

M

Michael C. Haffner *

DOI：10.1111/his.70033

Original

Original request for help

Save

Abstract

En 中文

Metastatic prostate cancer (mPC) is characterized by molecular and phenotypic heterogeneity. With increasing guideline-driven use of metastatic biopsies, more mPC specimens are being evaluated in surgical pathology. However, unlike localized prostate cancer, no standardized framework currently exists to guide the diagnostic workup of metastatic biopsies or reliably determine phenotypic subtypes. While many mPCs retain conventional acinar features, a growing subset exhibits phenotypic plasticity - including loss of prostate epithelial identity and emergence of neuroendocrine or other divergent lineages. This phenotypic diversity often occurs in castration-resistant prostate cancer as a mechanism of resistance to chronic androgen receptor pathway inhibition and is characterized by genomic alterations and epigenetic reprogramming. This review outlines the histologic and molecular spectrum of mPC and proposes a practical, pathology-informed diagnostic approach integrating morphologic assessment and immunohistochemistry. Adoption of a standardized diagnostic framework and multidisciplinary integration will be useful for employing precision oncology in advanced mPC.

Keywords:

heterogeneity

metastasis

molecular subtype

prostate cancer

Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis

Abstract

Journal

Organization